Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study

Fig. 3

Overall Survival Analysis of rPDAC patients who received different chemotherapy regimens. Patients who received standard combination; FOLFIRINOX and /or gemcitabine- nab-paclitaxel (tiny broken lines) compared to those who received other non-standard combinations (larger broken lines) and single agent therapy (solid line). The median OS; standard combinations was 14 months, non-standard and single agent therapy, 8 months. Log-rank p = 0.0295

Back to article page